Keyword: Axovant Sciences
Celgene's shake-ups continue with new CFO, Zai Lab grabs top AZ exec, Axovant brings on Spark co-founder as CTO, and Gilead promotes its top dealmaker.
Axovant is continuing its change-up with a new focus and a new exec.
Novartis' ex-oncology head jumps to startup; Axovant poaches Allergan's CMO; and Biogen brings on Pfizer dealmaker.
Alzheimer’s startup Cortexyme rounded up $76 million for a potentially first-in-class antibiotic treatment, while others struggle in the field.
Corcoran is stepping down as CMO of Allergan to take up the role, which will see him try to guide Axovant back from its Alzheimer’s failure.
Salomon Azoulay will serve as chief medical officer, while Adele Gulfo joins as chief of commercial development.
The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.
Axovant CEO Hung resigned, Arcturus CSO and COO Chivukula stepped down, Celgene spinoff emerged with Bob Hariri at the reins.
After a very brief and tumultuous tenure at startup Axovant with big hopes and backing, former Medivation chief David Hung, M.D., has resigned as CEO.
The deal ends Poxel’s long wait for a partner capable of running a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases.
